Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymph
8 hours ago
- #Chemoimmunotherapy
- #DLBCL
- #Epcoritamab
- Epcoritamab combined with R-DHAX/C shows deep and durable responses in R/R DLBCL patients.
- Overall response rate was 79%, with a complete response rate of 69%.
- 55% of patients proceeded to ASCT, a potentially curative treatment.
- At 36 months, 70% of responses were ongoing, 59% progression-free, and 76% survival rate.
- Common TEAEs included thrombocytopenia (90%), anemia (66%), and neutropenia (59%).
- Cytokine release syndrome occurred in 45% of patients, all grade 1-2, resolving in median 2 days.
- No fatal TEAEs or clinical tumor lysis syndrome were observed.
- Epcoritamab plus R-DHAX/C offers a manageable safety profile and effective salvage treatment.